S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Want To Catch The Next Hot Investing Trend (Look Inside?) (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
Microsoft strikes 10-year deal with Nintendo on Call of Duty
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo? (Ad)
Could trawler cams help save world's dwindling fish stocks?
Southwest Airlines brings back dividend as travel rebounds
NASDAQ:ILMN

Illumina - ILMN Stock Forecast, Price & News

$208.52
+2.54 (+1.23%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$206.35
$211.12
50-Day Range
$187.24
$242.74
52-Week Range
$173.45
$428.00
Volume
932,307 shs
Average Volume
1.32 million shs
Market Capitalization
$32.80 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$254.38

Illumina MarketRank™ Forecast

Analyst Rating
Hold
2.42 Rating Score
Upside/​Downside
22.8% Upside
$256.00 Price Target
Short Interest
Healthy
2.78% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
0.14mentions of Illumina in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$220,120 Sold Last Quarter
Proj. Earnings Growth
32.78%
From $2.41 to $3.20 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.80 out of 5 stars

Medical Sector

59th out of 1,027 stocks

Analytical Instruments Industry

3rd out of 28 stocks

ILMN stock logo

About Illumina (NASDAQ:ILMN) Stock

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.

Receive ILMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.

ILMN Stock News Headlines

Illumina (NASDAQ:ILMN) Coverage Initiated at Royal Bank of Canada
Let's Shine Another Light on Dimming Illumina
Want To Catch The Next Hot Investing Trend (Look Inside?)
While millennials are trying to get rich in crypto Ponzi schemes- there's something happening that Wall Street is TOTALLY ignoring. And it's about to affect every American Citizen over 55...
The WORST National Security Threat To The USA Since The 1973 Arab Oil Embargo?
Communist China has the USA in a resource stranglehold. They have a monopoly on this CRITICAL metal that we desperately need for military technology. In fact, both Trump AND Biden passed executive orders that addressed this crisis. And it could have a massive effect on smart investor's bank accounts.
Illumina Supports Next Generation Scientists at Genspace
Illumina Slashes 5% Of Its Workforce
Shares of Illumina Have Been Bottoming
UPDATE 1-Illumina cuts 5% of its workforce
Greenwood Genetic Center: Answering the Unanswered
Rarebase Is on the Hunt for Therapeutic Opportunities
See More Headlines
Receive ILMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.

ILMN Company Calendar

Last Earnings
11/03/2022
Today
12/07/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/09/2023

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:ILMN
CUSIP
45232710
Employees
9,150
Year Founded
1998

Price Target and Rating

Average Stock Price Forecast
$256.00
High Stock Price Forecast
$350.00
Low Stock Price Forecast
$175.00
Forecasted Upside/Downside
+22.0%
Consensus Rating
Hold
Rating Score (0-4)
2.42
Research Coverage
13 Analysts

Profitability

Net Income
$762 million
Pretax Margin
-86.87%

Debt

Sales & Book Value

Annual Sales
$4.53 billion
Cash Flow
$7.33 per share
Book Value
$68.71 per share

Miscellaneous

Free Float
157,096,000
Market Cap
$32.80 billion
Optionable
Optionable
Beta
1.13

Social Links


Key Executives

  • Mr. Francis A. deSouzaMr. Francis A. deSouza (Age 51)
    CEO & Director
  • Dr. Alexander Aravanis M.D.Dr. Alexander Aravanis M.D. (Age 45)
    Ph.D., CTO & Head of Research and Product Devel.
    Comp: $1.05M
  • Mr. Charles E. DadswellMr. Charles E. Dadswell (Age 63)
    Sr. VP, Gen. Counsel & Sec.
  • Ms. Susan H. TousiMs. Susan H. Tousi (Age 53)
    Chief Commercial Officer
    Comp: $1.04M
  • Stephanie Campos
    Pres
  • Dr. Joydeep Goswami M.B.A. (Age 51)
    Ph.D., Chief Strategy & Corp. Devel. Officer and Interim CFO
  • Mr. Kevin Carl Pegels
    Chief of Global Operations
  • Mr. Scott Ericksen (Age 50)
    VP & Chief Accounting Officer
  • Ms. Carissa Rollins
    Chief Information Officer
  • Ms. Sallilyn Schwartz
    VP of Investor Relations













ILMN Stock - Frequently Asked Questions

Should I buy or sell Illumina stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ILMN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View ILMN analyst ratings
or view top-rated stocks.

What is Illumina's stock price forecast for 2023?

13 Wall Street research analysts have issued 1 year target prices for Illumina's shares. Their ILMN share price forecasts range from $175.00 to $350.00. On average, they predict the company's stock price to reach $256.00 in the next twelve months. This suggests a possible upside of 22.8% from the stock's current price.
View analysts price targets for ILMN
or view top-rated stocks among Wall Street analysts.

How have ILMN shares performed in 2022?

Illumina's stock was trading at $380.44 at the start of the year. Since then, ILMN shares have decreased by 45.2% and is now trading at $208.52.
View the best growth stocks for 2022 here
.

Are investors shorting Illumina?

Illumina saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 4,370,000 shares, a decline of 9.3% from the October 31st total of 4,820,000 shares. Based on an average daily trading volume, of 1,620,000 shares, the short-interest ratio is presently 2.7 days.
View Illumina's Short Interest
.

When is Illumina's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 9th 2023.
View our ILMN earnings forecast
.

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) announced its earnings results on Thursday, November, 3rd. The life sciences company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.29 by $0.05. The life sciences company had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.10 billion. Illumina had a positive trailing twelve-month return on equity of 4.36% and a negative net margin of 88.40%.

What guidance has Illumina issued on next quarter's earnings?

Illumina issued an update on its FY 2022 earnings guidance on Thursday, November, 10th. The company provided EPS guidance of $2.35-$2.50 for the period, compared to the consensus earnings per share estimate of $2.78. The company issued revenue guidance of $4.53 billion-$4.57 billion, compared to the consensus revenue estimate of $4.71 billion.

What is Francis deSouza's approval rating as Illumina's CEO?

496 employees have rated Illumina Chief Executive Officer Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among the company's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Walt Disney (DIS), PayPal (PYPL), Salesforce (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

What is Illumina's stock symbol?

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

Who are Illumina's major shareholders?

Illumina's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (12.11%), Vanguard Group Inc. (8.16%), Edgewood Management LLC (4.72%), Polen Capital Management LLC (2.88%), Veritas Asset Management LLP (1.01%) and Alliancebernstein L.P. (1.00%). Insiders that own company stock include Aimee L Hoyt, Alexander Aravanis, Charles Dadswell, Frances Arnold, Francis A Desouza, Francis A Desouza, Jay T Flatley, Karen K Mcginnis, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Sam Samad, Susan H Tousi and Susan H Tousi.
View institutional ownership trends
.

How do I buy shares of Illumina?

Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Illumina's stock price today?

One share of ILMN stock can currently be purchased for approximately $208.52.

How much money does Illumina make?

Illumina (NASDAQ:ILMN) has a market capitalization of $32.80 billion and generates $4.53 billion in revenue each year. The life sciences company earns $762 million in net income (profit) each year or ($26.40) on an earnings per share basis.

How many employees does Illumina have?

The company employs 9,150 workers across the globe.

Does Illumina have any subsidiaries?
The following companies are subsidiares of Illumina: Advanced Liquid Logic Inc., Affomix Corporation, BlueBee, BlueBee Belgium BVBA, BlueBee Holding BV, BlueGnome Ltd, BlueGnome Ltd., Conexio Genomics, Conexio Genomics Pty Ltd., Edico Genome, Emedgene Inc., Emedgene Technologies Ltd, Enancio, Enancio SAS, Epicentre Biotechnologies, GRAIL LLC, GenoLogics, Grail, Helixis, Illumina (China) Scientific Co Ltd, Illumina AB, Illumina Australia Pty. Ltd., Illumina Belgium BVBA, Illumina Brasil Produtos de Biotecnologia Ltda., Illumina Cambridge Ltd., Illumina Canada ULC, Illumina Denmark ApS, Illumina Finland Oy, Illumina France Sarl, Illumina GmbH, Illumina Hong Kong Limited, Illumina India Biotechnology Private Limited, Illumina Ireland Commercial Limited, Illumina Italy S.r.l., Illumina K.K. Japan, Illumina Korea Ltd., Illumina Netherlands B.V., Illumina New Zealand Limited, Illumina Norway AS, Illumina Productos de Espana S.L.U., Illumina Rus LLC, Illumina Shanghai (Trading) Co Ltd Beijing Branch, Illumina Shanghai (Trading) Co. Ltd., Illumina Singapore Pte. Ltd., Illumina Software Inc., Illumina Switzerland GmbH, Illumina US Manufacturing Operations Inc., Liquid Logic, Moleculo, NextBio, Solexa, Verinata Health, Verinata Health Inc., and thromboDx BV.
Read More
How can I contact Illumina?

Illumina's mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The official website for the company is www.illumina.com. The life sciences company can be reached via phone at (858) 202-4500, via email at ir@illumina.com, or via fax at 858-202-4766.

This page (NASDAQ:ILMN) was last updated on 12/8/2022 by MarketBeat.com Staff